SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (582)4/20/1999 9:48:00 PM
From: William Whitehead Jr.  Respond to of 2344
 
That's a very well thought out message - most importantly it deals in reasonable time frames. Given the pipeline of potential vaccines this company could potentially hit a home run in a number of different areas.

Whitey,



To: StockMiser who wrote (582)4/21/1999 11:01:00 AM
From: Michael Brody  Read Replies (2) | Respond to of 2344
 
StockMiser,
The " If " in your statement on Theratope's efficacy with
Stem Cell combination is no longer an " If " . Check out the
Fred Hutchinson Cancer Center site under reseacher "Sandmaier".
Her quote on the study is that " preliminary results indicate a
immunological response" induced by Theratope with Stem cell
therapy. Also, no side effects. Hope this helps.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News